CFTR corrector + potentiator
Tezacaftor with ivacaftor
Brand names: Symkevi
Adult dose
Dose: 100/150mg PO morning + 150mg ivacaftor PO evening
Route: PO
Frequency: BD
Clinical pearls
- CF F508del homozygous or heterozygous with residual function mutation
- Specialist CF centre; superseded by Kaftrio for many
Contraindications
- Severe hepatic impairment
- Concurrent strong CYP3A4 inducers
- Hypersensitivity
Side effects
- Headache
- Hepatotoxicity
- Cataracts (paeds)
- Respiratory events
- Rash
Interactions
- Strong CYP3A4 modulators
- Hormonal contraceptives
Monitoring
- LFTs
- Eye exam (paeds)
Reference: BNF; NICE TA716; SmPC; https://bnf.nice.org.uk/drugs/tezacaftor-with-ivacaftor/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024